MedTrace Logo

Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

NCT02753764 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-08-21

No results posted yet for this study

Summary

This is a double-blind, placebo controlled 4 week crossover study to investigate the efficacy and safety of AZD7624 (an inhaled p38 inhibitor) in corticosteroid resistant (CR) asthmatics. For the purpose of this study 10 symptomatic CR asthma patients with a FEV1% predicted \<80% and normal bronchodilator response, 10 CS asthmatics and 10 healthy controls will be recruited.

Conditions

  • Corticosteroid Resistant (CR) Asthmatics

Interventions

DRUG

AZD7624

DRUG

prednisone

oral prednisone 20 mg bid for one week

DRUG

Placebo

Sponsors & Collaborators

  • National Jewish Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2019-02-25
Completion
2019-02-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02753764 on ClinicalTrials.gov